ZGNX News and Press, Zogenix Inc. From 02/13/20

Zogenix offers Data for Fintepla, Markets React Negatively Zogenix (ZGNX) stock tumbled as the company reported mixed data from its Phase 3 clinical trial of Fintepla. The trial involved evaluating two doses of the lead drug candidate in patients suffering from a severe form of childhood o...

Zogenix (NASDAQ: ZGNX) reported what it called "positive" results from a late-stage clinical trial testing its drug candidate, Fintepla, in patients with a variety of childhood-onset epilepsy called Lennox-Gastaut syndrome. And technically, the company was right: Fintepla reduced the median ...

Gainers: Benitec Biopharma (NASDAQ: BNTC )  +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...

Shares of Zogenix (NASDAQ: ZGNX) fell more than 32% today after the company reported positive top-line results from an important phase 3 study evaluating Fintepla as a treatment for a rare childhood form of epilepsy called Lennox-Gastaut syndrome (LGS). While the drug candidate achieved a st...

Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Zogenix (NASDAQ: ZGNX ) slumps  33%  after hours in reaction to its announcement of "successful" results from a Phase 3 clinical trial evaluating two doses of Fintepla (fenfluramine oral solution) (ZX008) in patients with a severe form of childhood-onset epilepsy called Lennox-...

Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo   FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints   Zogenix to Host Conference Call and Live Webcast...

This was expected to be the year that everything went right for the cannabis industry . To our north, Canada had become the first industrialized country in the world to legalize recreational marijuana and commenced sales in October 2018. Derivative products were also presumed to hit dispensary ...

Zogenix (NASDAQ: ZGNX )  announces that The Lancet has published the results of its Phase 3 trial for Fintepla in children and young adults with Dravet syndrome, a rare, catastrophic form of epilepsy. More news on: Zogenix, Inc., Healthcare stocks news, Read more ...

FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare ...